It is very uncertain whether combination therapy changes cardiovascular events compared with monotherapy (very low certainty).
It is very uncertain whether combination therapy changes serious adverse events compared with monotherapy (very low certainty).
It is very uncertain whether combination therapy changes withdrawals due to adverse effects compared with monotherapy (very low certainty).
It is very uncertain whether combination with potassium‐sparing diuretics changes total mortality compared with monotherapy (very low certainty).
It is very uncertain whether combination with potassium‐sparing diuretics changes cardiovascular events compared with monotherapy (very low certainty).
It is very uncertain whether combination with potassium‐sparing diuretics changes serious adverse events compared with monotherapy (very low certainty).
Renin inhibitors showed no clear difference in all‐cause mortality compared with ACE inhibitors (low certainty).
It is very uncertain whether renin inhibitors changes fatal or non‐fatal myocardial infarction compared with ACE inhibitors (very low certainty).
Renin inhibitors showed no clear difference in adverse events compared with ACE inhibitors (moderate certainty).
Renin inhibitors showed no clear difference in fatal or non‐fatal serious adverse events compared with ACE inhibitors (low certainty).
Renin inhibitors showed no clear difference in withdrawal due to adverse effects (WDAE) compared with ACE inhibitors (low certainty).
Prostacyclin probably leads to higher improvement in WHO functional class compared with control (moderate certainty).
Selexipag showed no clear difference in improvement in WHO functional class compared with placebo (moderate certainty).